The lack of a meaningful signal of Denvatirsen (ASO inhibitor of STAT3) + pembrolizumab in RM #HNSCC should not close the door on future targeting of STAT3 in the context of immunotherapy in #HNSCC @AACR @marshposnermd @sitcancer @DrEzraCohen @WinshipAtEmory
Now online: Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial. doi.org/10.1158/1078-0…View quoted post on X